# NASOPHARYNX MALIGNANT NEOPLASM

MOHAMMED ALESSA MBBS, FRCSC ASSISTANT PROFESSOR, CONSULTANT OTOLARYNGOLOGY, HEAD & NECK SURGRY KING SAUD UNIVERSITY

- Epidemiology
- Anatomy

- Histopathology
- Clinical presentation
- Diagnosis --- serology
- Imaging studies
- Staging
- Treatment
- Persistent / recurrent disease Rx ( Re- irradiation)

# Epidemiology

- 2<sup>nd</sup> most common head & neck malignancy in Saudi Arabia.
  0.7% of all cancers.
- It occurs more frequently in southern province
- Younger age group, (M:F, 3:1)
- Genetic, ethnic, environmental factors (salted fish).
- HPV & EBV has also been considered to play an oncogenic role in this tumor --- Ab (EA, VCA)
- Tumor suppressor genes :
  - Losses on chromosomes 3p, 9p, 11q, 13q, and 14q

## Epidemiology


• High index of suspicion required for early diagnosis .


Nasopharyngeal malignancies :

- SCCA (nasopharyngeal carcinoma)
- Lymphoma
- Salivary gland tumors
- Sarcoma
- Brian tumor (extracranial extension)
- Mets

# Anatomy subsites

- Postero-superior wall
- Lateral wall (including the fossa of Rosenmüller)
  - Most common site NPC
- Inferior wall (=superior surface of the soft palate)






#### Anatomy

- Retropharyngeal nodes (nodes of Rouviere).
- Level II .
- Level VA.
- \*Bilateral disease is common.

most common site of distant Mets
( highest rate in Head & Neck):

Bone



# Histopathology

World Health Organization (WHO) **1978**:

- Type I : keratinizing SCCs
- Type II : non keratinizing epidermoid carcinomas.
- Type III: undifferentiated carcinomas or poorly differentiated carcinoma.( most common subtype in Saudi Arabia , Southern China , North America ).

- WHO **1991**
- Group 1 : SCC or non keratinizing CA
- Group 2 : Differentiated and
- Undifferentiated carcinomas

**\*\*** EBV titre , local control , distant metastasis .



- Clinical examination ---- Neck , ear & CN exam
- Nasal endoscopy
- Imaging studies
- FNA Cytology
- NP biopsy
- Serology

### **Clinical presentation**


- Delay in Dx (advanced stage on presentation):
  - Nonspecific nature of the nasal and aural symptoms
  - Painless cervical lymph node.


- Adult ,unilateral SOM
  - NPC until proven otherwise (Nasal endoscopy is mandatory)

Cervical LAP	76%
Nasal symptoms	73%
Aural symptoms	62%
Cranial N	20%

## **Clinical presentation**


- Xerophthalmia greater sup. petrosal n
- ➢ Facial pain Trigeminal n.
- Diplopia CN VI (most common)
- Ophthalmoplegia CN III, IV, and VI cavernous sinus or superior orbital fissure
- Horner's syndrome cervical sympathetics
- CN's IX, X, XI, XII extensive skull base





## Nasal endoscopy

- Obtain adequate decongestant as well as topical anesthesia
- Flexible vs rigid endoscopy
- Same sett diagnostic biopsy should be done.



## Nasal endoscopy

	Flexible	Rigid
Size	Pedia , adult	2.5, 3, 4 mm
Angle		0,30,70
Image resolution		Superior
Side port ( suction , biopsy forceps)	yes	

## Imaging

- Computed Tomography (CT scan)
- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET)
- Bone scan


## **Computed tomography (CT)**


- Sensitive in detecting bone erosion (skull base) & intracranial extension.
- Bone regeneration after therapy
   complete eradication of tumor .
- Better assessment of cervical lymphadenopathy



## Magnetic resonance imaging (MRI)

- Better assessment of tumor enhancement as well as perineural invasion .
- Sensitive in differentiation of tumor vs inflammatory process.





# **Positron emission tomography (PET)**

- Assessment of distant metastasis.
- valuable modality in prognostic evaluation
  - SUV max > 5 ----- poor outcome
- Provide functional information of loco regional recurrence



## Serology – EBV

- IgG EA ---- diagnosis
- IgA VCA ---- Rx response as well as tumor recurrence .
- (ADCC) ---- higher titers indicate a better long-term prognosis
   EDV DNA
- EBV DNA

- More sensitive than Ab in diagnosis & distant Mets.
- Initial RT phase , increase serum level
- Monitor tumor recurrence.
- LFT --- liver Mets

## **Cyto-pathology**

- FNA Cytology :
   EBV ISH occult UNPC
- Nasopharyngeal biopsy (endoscopic) :
  - IHC helpful to differentiate nasopharyngeal malignancies .
  - EBV Staining ---- EBER
  - HPV staining --- P 16 & HPV DNA



- American Joint Committee on Cancer Staging (AJCC)--- North America
- Union International Contre le Cancer (UICC) --- Europe Ho system ---Asia.

### Staging : nasopharynx (T)

classification T stage	Но	AJCC ( 2010)
Tı	Nasopharynx	<ul><li>Nasopharynx</li><li>Oropharynx , nasal cavity</li><li>w/out PPS extension</li></ul>
Τ2	Nasal fossa, oropharynx, parapharynx, muscle/nerves below base of skull	PPS extension
Т3	A: Bone below base of skull; B:. bone at base of skull; C: cranial nerve; d. orbit, infratemporal fossa, laryngopharynx	Skull base PNS
Т4		CN , orbit , hypopharynx ITF , masticator space.

## Staging: nasopharynx(N)

classification N	Но	AJCC ( 2010)
Νο	None	None
Nı	Upper neck	Unilateral < 6 cm retropharyngeal lymph nodes
N2	Mid neck	Bilateral < 6 cm
N3	SCF	A: > 6 cm B : SCF

# Staging : nasopharynx groups

classification Group	НО	AJCC (2010)
I	T1No	TıNo
II	T2No T1N1	A: T2aNo B: T2bNo , T1,2a N1
111	T3N0-2 T1-2N2	T3N0-2 T1-2bN2
IV	T1-3N3 T1-4N3 T1-4N0-3M1	A: T4No-2 B: Any N3 C: Any M1
V	T1-4N0-3M1	



#### Treatment

- Multidisciplinary plans
- Medical plans

## Treatment multidisciplinary plan

Dental evaluation

- Swallowing & speech assessment
- Nutritional status
- Audiological assessment
- Psychological counseling .

#### Treatment

- Primary tumor treatment
- Neck (lymph node) treatment.
- Persistent /recurrent (loco regional) disease.
- Eustachian tube dysfunction (ETD).

### Treatment Nasopharynx

#### **Radiation therapy (RT)**

- Conformal RT --- evolution
- Intensity modulated (IMRT) -- treatment of choice
- Brachytherapy ---- booster does
- Stereotactic (SRT) --- booster does
- 65-75 Gy

- Local control :
  - 75-90% ----- T1&2
  - 50-75% -----T3,4


#### Surgery --- nasopharyngectomy

- Challenging with Major morbidities
- Inferior result in comparison to RT



#### Advantages :

- The dose differential between the tumor and the dose-limiting organs.
- High dose can be conformed to match the target while selective avoidance of dose to critical structures can be achieved at the same time.
- Ability to treat primary and regional lymphatic in one volume.
- local control rate of 92% to 97% at 3 to 4 years.





#### Disadvantages :

- Precision of determining the junction of tumor and the adjacent normal structures .
- Accurate determination of the safety margin

# Treatment Lymph nodes


#### RT

- Conformal RT
- IMRT

#### **Surgery :**

Neck dissection – treat according to primary tumor

Bilateral drainage mandate treatment of both neck



#### N0:

- Is observation an option ?
- Rate of occult Mets : 20-30%
- **50-60** Gy
- Regional control : 90%

#### >N0:

- 65-70 Gy
- **Control** : 70%

## Chemotherapy

#### Indication :

- Primary : T3,4
- Lymph node : >N0
- Mode of administration :
  - Neo, concurrent or adjuvant
- Concurrent CTRT Improve survival in comparison to RT alone :
   (56% to 62%), 5 years survival

## Chemotherapy

- **Cisplatin**-based regimens have been found to be the most effective, multiple phase III trials.
- Dose : (100 mg/m2 q three weeks) to radiation therapy ,
   (70 Gy/seven weeks).

# Persistent, Recurrent NPC (local) Diagnosis

- Incidence of failure was around 8.3%
- Successful salvage rate :

- Early detection & administration of the appropriate therapy.
- PET /CT scan --- imaging of choice.
- Presence of malignancy
  - Biopsy through endoscopic examination.

# Persistent, Recurrent NPC (local) management

#### RT (small & localized disease)

IMRT

- Salvage rate : 32%
- Post-re irradiation sequelae : 24%
- Mortality of : 1.8%
- **SRT** ---- 83% , 3 years local control
- Brachytherapy

#### Surgery ---- nasopharyngectomy

- Extension into the paranasopharyngeal space.
- Too bulky for brachytherapy to be successful.

# Persistent, Recurrent NPC (local) nasopharyngectomy

#### Endoscopic :

Small, posterior pharyngeal wall

#### External approaches

- Infratemporal fossa
- Transparotid temporal bone approach
- Transmaxillary
- Transmandibular
- Transpalatal

# Persistent, Recurrent NPC (regional) diagnosis

- Notoriously difficult to confirm,
  - Iymph nodes : clusters of tumor cells were present.
- PET/CT --- superior to CT & MRI
- FNA Cytology ---- 50% diagnostic
- Is excisional biopsy has a role in diagnosis ?


# Persistent , Recurrent NPC ( regional) management

#### Surgery

- Radical neck dissection (salvage)
- 66%, 5 years regional control

#### • <u>RT</u>

- Brachytherapy ( intra operative , adjuvant ):
  - Extension beyond the confines of the lymph node( floor of the neck)
  - 60 % , 5 years control





#### Bilateral tube insertion if symptomatic prior to RT Post RT

- observation period if symptoms not severe
- amplification may be more appropriate

### Conclusion

- NPC is common among southern Chinese, and a combination of genetic, viral, and environmental factors contributes to the etiology.
- The diagnosis of NPC depends on the clinical features, serologic tests, and imaging features.
- The confirmation of the disease is through endoscopic examination and biopsy.
- The extent of the disease is determined by clinical examination, imaging studies, and endoscopic findings.

### Conclusion

- The treatment of early stage NPC is by radiation alone while for advanced stage disease, concurrent chemoradiation gives the best outcome.
- The incidence of local/regional residual of recurrent disease after radiation/chemoradiation is around 10% .

• Outcome of salvage with further radiation, brachytherapy, and surgery depends on the extent of the disease.

### Conclusion

- For salvage of localized lymph nodes confined to the neck, surgery with neck dissection gives satisfactory results.
- The choice of surgical approach for resection of recurrent NPC in the nasopharynx depends on the size, location, extent of disease, and condition of the patient.
- In general, the 5-year local tumor control rate following surgical salvage is around 74% and the 5-year disease-free survival rate is 56%.

# THANK YOU